Table 2. Treatment received at first relapse for all relapsed neuroblastoma cases, high risk cases and intermediate risk, stage 3, unresectable, non-MNA neuroblastoma.
| All relapsed cases N (%) | High Risk N (%) | Intermediate risk N (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment | Diagnosed ⩽2000 | Diagnosed >2000 | Total | Diagnosed ⩽2000 | Diagnosed >2000 | Total | Diagnosed ⩽2000 | Diagnosed >2000 | Total |
| Second-line Chemotherapya | 29 (36.3) | 33 (38.4) | 62 (37.4) | 22 (34.4) | 29 (39.2) | 51 (37.0) | 2 (22.2) | 1 (14.3) | 3 (18.8) |
| Combination of treatmentsb | 15 (118.8) | 17 (19.8) | 32 (19.3) | 10 (15.6) | 12 (16.20 | 22 (15.9) | 4 (44.4) | 4 (57.1) | 8 (50.0) |
| mIBG therapy | 1 (1.3) | 6 (7.0) | 7 (4.2) | 1 (1.6) | 6 (8.1) | 7 (5.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Other (e.g., surgery or radiotherapy) | 7 (8.8) | 10 (11.6) | 17 (10.2) | 4 (6.3) | 8 (10.8) | 12 (8.7) | 2 (22.2) | 2 ( 28.6) | 4 (25.0) |
| Phase I or II trials | 5 (6.3) | 5 (5.8) | 10 (6.0) | 5 (7.8) | 5 (6.8) | 10 (7.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Palliative radiotherapy | 10 (12.5) | 6 (7.0) | 16 (9.6) | 10 (15.6) | 6 (8.1) | 16 (11.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Supportive care | 13 (16.3) | 9 (10.5) | 22 (13.3) | 12 (18.8) | 8 (10.8) | 20 (14.5) | 1 (11.1) | 0 (0.0) | 1 (6.3) |
| Total | 80 (100) | 86 (100) | 166 (100) | 64 (100) | 74 (100) | 138 (100) | 9 (100) | 7 (100) | 16 (100) |
a
Second-line chemotherapy includes vincristine, temozolamide, irinotecan, topotecan vincristine-doxorubicin or oral etoposide.
b
Combination of chemotherapy, surgery, radiotherapy and miBG therapy.